Non-specific effects of inactivated Mycobacterium bovis oral and parenteral treatment in a rabbit scabies model

Tuberculosis BCG vaccination induced non-specific protective effects in humans led to postulate the concept of trained immunity (TRAIM) as an innate type of immune mechanism that triggered by a pathogen, protects against others. Killed vaccines have been considered not to be effective. However, fiel...

Descripción completa

Detalles Bibliográficos
Autores: Casais, Rosa, Iglesias, Natalia, Sevilla, Iker A, Garrido, Joseba M, Balseiro, Ana, Dominguez-Rodriguez, Mercedes, Juste, Ramón A
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/26543
Acceso en línea:https://hdl.handle.net/20.500.12105/26543
Access Level:acceso abierto
Palabra clave:Mycobacterium bovis
Sarcoptes scabiei
Killed vaccine
Scabies
Serology
Trained immunity
Tuberculosis
Animals
BCG Vaccine
Enzyme-Linked Immunosorbent Assay
Humans
Immunity, Humoral
Rabbits
Vaccines, Inactivated
id ES_e948fe82ceccc32b6a714aee58e017a2
oai_identifier_str oai:repisalud.isciii.es:20.500.12105/26543
network_acronym_str ES
network_name_str España
repository_id_str
spelling Non-specific effects of inactivated Mycobacterium bovis oral and parenteral treatment in a rabbit scabies modelCasais, RosaIglesias, NataliaSevilla, Iker AGarrido, Joseba MBalseiro, AnaDominguez-Rodriguez, MercedesJuste, Ramón AMycobacterium bovisSarcoptes scabieiKilled vaccineScabiesSerologyTrained immunityTuberculosisAnimalsBCG VaccineEnzyme-Linked Immunosorbent AssayHumansImmunity, HumoralMycobacterium bovisRabbitsScabiesTuberculosisVaccines, InactivatedTuberculosis BCG vaccination induced non-specific protective effects in humans led to postulate the concept of trained immunity (TRAIM) as an innate type of immune mechanism that triggered by a pathogen, protects against others. Killed vaccines have been considered not to be effective. However, field efficacy of a commercial vaccine against paratuberculosis, as well as of a recently developed M. bovis heat-inactivated vaccine (HIMB) prompted to test whether it could also induce TRAIM. To this, we used a sarcoptic mange rabbit model. Twenty-four weaned rabbits were treated orally or subcutaneously with a suspension of either HIMB (107 UFC) or placebo. Eighty-four days later the animals were challenged with approximately 5000 S. scabiei mites on the left hind limb. Skin lesion extension was measured every 2 weeks until 92 days post-infection (dpi). Two animals were killed at 77 dpi because of extensive skin damage. The rest were euthanized and necropsied and the lesion area and the mite burden per squared cm were estimated. Specific humoral immune responses to S. scabiei and to M. bovis were investigated with the corresponding specific ELISA tests. Subcutaneously and orally HIMB vaccinated animals compared with placebo showed reduced lesion scores (up to 74% and 62%, respectively) and mite counts (-170% and 39%, respectively). This, together with a significant positive correlation (r = 0.6276, p = 0.0031) between tuberculosis-specific antibodies and mite count at 92 dpi supported the hypothesis of non-specific effects of killed mycobacterial vaccination. Further research is needed to better understand this mechanism to maximize cross protection.BioMed Central (BMC)Gobierno del Principado de Asturias (España)Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)20252025-03-2020242024-03-2620242024-03-26research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.12105/26543reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/265432026-06-12T12:43:37Z
dc.title.none.fl_str_mv Non-specific effects of inactivated Mycobacterium bovis oral and parenteral treatment in a rabbit scabies model
title Non-specific effects of inactivated Mycobacterium bovis oral and parenteral treatment in a rabbit scabies model
spellingShingle Non-specific effects of inactivated Mycobacterium bovis oral and parenteral treatment in a rabbit scabies model
Casais, Rosa
Mycobacterium bovis
Sarcoptes scabiei
Killed vaccine
Scabies
Serology
Trained immunity
Tuberculosis
Animals
BCG Vaccine
Enzyme-Linked Immunosorbent Assay
Humans
Immunity, Humoral
Mycobacterium bovis
Rabbits
Scabies
Tuberculosis
Vaccines, Inactivated
title_short Non-specific effects of inactivated Mycobacterium bovis oral and parenteral treatment in a rabbit scabies model
title_full Non-specific effects of inactivated Mycobacterium bovis oral and parenteral treatment in a rabbit scabies model
title_fullStr Non-specific effects of inactivated Mycobacterium bovis oral and parenteral treatment in a rabbit scabies model
title_full_unstemmed Non-specific effects of inactivated Mycobacterium bovis oral and parenteral treatment in a rabbit scabies model
title_sort Non-specific effects of inactivated Mycobacterium bovis oral and parenteral treatment in a rabbit scabies model
dc.creator.none.fl_str_mv Casais, Rosa
Iglesias, Natalia
Sevilla, Iker A
Garrido, Joseba M
Balseiro, Ana
Dominguez-Rodriguez, Mercedes
Juste, Ramón A
author Casais, Rosa
author_facet Casais, Rosa
Iglesias, Natalia
Sevilla, Iker A
Garrido, Joseba M
Balseiro, Ana
Dominguez-Rodriguez, Mercedes
Juste, Ramón A
author_role author
author2 Iglesias, Natalia
Sevilla, Iker A
Garrido, Joseba M
Balseiro, Ana
Dominguez-Rodriguez, Mercedes
Juste, Ramón A
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Gobierno del Principado de Asturias (España)
Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.subject.none.fl_str_mv Mycobacterium bovis
Sarcoptes scabiei
Killed vaccine
Scabies
Serology
Trained immunity
Tuberculosis
Animals
BCG Vaccine
Enzyme-Linked Immunosorbent Assay
Humans
Immunity, Humoral
Mycobacterium bovis
Rabbits
Scabies
Tuberculosis
Vaccines, Inactivated
topic Mycobacterium bovis
Sarcoptes scabiei
Killed vaccine
Scabies
Serology
Trained immunity
Tuberculosis
Animals
BCG Vaccine
Enzyme-Linked Immunosorbent Assay
Humans
Immunity, Humoral
Mycobacterium bovis
Rabbits
Scabies
Tuberculosis
Vaccines, Inactivated
description Tuberculosis BCG vaccination induced non-specific protective effects in humans led to postulate the concept of trained immunity (TRAIM) as an innate type of immune mechanism that triggered by a pathogen, protects against others. Killed vaccines have been considered not to be effective. However, field efficacy of a commercial vaccine against paratuberculosis, as well as of a recently developed M. bovis heat-inactivated vaccine (HIMB) prompted to test whether it could also induce TRAIM. To this, we used a sarcoptic mange rabbit model. Twenty-four weaned rabbits were treated orally or subcutaneously with a suspension of either HIMB (107 UFC) or placebo. Eighty-four days later the animals were challenged with approximately 5000 S. scabiei mites on the left hind limb. Skin lesion extension was measured every 2 weeks until 92 days post-infection (dpi). Two animals were killed at 77 dpi because of extensive skin damage. The rest were euthanized and necropsied and the lesion area and the mite burden per squared cm were estimated. Specific humoral immune responses to S. scabiei and to M. bovis were investigated with the corresponding specific ELISA tests. Subcutaneously and orally HIMB vaccinated animals compared with placebo showed reduced lesion scores (up to 74% and 62%, respectively) and mite counts (-170% and 39%, respectively). This, together with a significant positive correlation (r = 0.6276, p = 0.0031) between tuberculosis-specific antibodies and mite count at 92 dpi supported the hypothesis of non-specific effects of killed mycobacterial vaccination. Further research is needed to better understand this mechanism to maximize cross protection.
publishDate 2024
dc.date.none.fl_str_mv 2024
2024-03-26
2024
2024-03-26
2025
2025-03-20
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.12105/26543
url https://hdl.handle.net/20.500.12105/26543
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv BioMed Central (BMC)
publisher.none.fl_str_mv BioMed Central (BMC)
dc.source.none.fl_str_mv reponame:Repisalud
instname:Instituto de Salud Carlos III (ISCIII)
instname_str Instituto de Salud Carlos III (ISCIII)
reponame_str Repisalud
collection Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423014460784640
score 15,811543

Similares en LA Referencia